Featured Product
Advertisement
IBD Drug Development Tools: TL1A Recombinant Proteins and Overexpression Cell Lines
IBD is one of important autoimmune disease, including ulcerative colitis and Crohn's disease. Drug treatment targeting TL1A can effectively alleviate the clinical symptoms of IBD. In order to meet the development of drugs targeting the TL1A / DR3 pathway, ACROBiosystems has developed high-quality TL1A recombinant proteins and overexpression cell line products to meet the needs of antibody drug development and accelerate drug development process!
About ACROBiosystems
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed for discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated to innovation to simplify and accelerate the development of new, better, and more affordable medicine.
Our way of addressing challenges in biologics development is to offer a comprehensive array of tools and solutions designed for each development phase. Starting from discovery and development and moving beyond commercialization, we strive to deliver high-quality solutions that support each step of the development process. This means bringing together innovation and technology through product development and collaborations to help our customers achieve translatable results in the clinic and beyond.
Interested in seeing more content from ACROBiosystems ?
Discover all their latest news, webinars, products and more by clicking the link below.
